EGFR and metastatic colorectal cancer: Recent studies showed that other activating mutations in KRAS (exons 3 and 4) or NRAS (exons 2, 3 and 4), in addition to KRAS mutation in exon 2 are also associated with poor prognosis or resistance to anti-EGFR antibody in metastatic colorectal cancer.